The inhibitory efficacy of RNA Pol III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5′ long terminal repeat

Oligonucleotides

Volumn 17, Issue 4, 2007, Pages 419-431

  Barichievy, Samantha ^a   Saayman, Sheena ^a   Von Eije, Karin J ^b   Morris, Kevin V ^c   Arbuthnot, Patrick ^a   Weinberg, Marc S ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; DNA DIRECTED RNA POLYMERASE III; INTERFERON; LONG HAIRPIN RNA; LUCIFERASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; URACIL; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TARGETING; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPETENT CELL; LENTIVIRINAE; LONG TERMINAL REPEAT; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; RNA SEQUENCE; RNA STRUCTURE; UNTRANSLATED REGION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

BASE SEQUENCE; CELL LINE; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; INTERFERON-BETA; MOLECULAR SEQUENCE DATA; RNA INTERFERENCE; RNA POLYMERASE III; RNA, ANTISENSE; RNA, SMALL INTERFERING; TRANSFECTION; UNTRANSLATED REGIONS;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 37549055424     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2007.0095     Document Type: Article

References (51)

1. AKASHI, H., MIYAGISHI, M., YOKOTA, T., WATANABE, T., HINO, T., NISHINA, K., KOHARA, M., and TAIRA, K. (2005). Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol. Biosyst. 1, 382-390.
2. AN, D.S., QIN, F.X., AUYEUNG, V.C., MAO, S.H., KUNG, S.K., BALTIMORE, D., and CHEN, I.S. (2006). Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol. Ther. 14, 494-504.
3. ANDERSON, J., and AKKINA, R. (2005). HIV-1 resistance conferred by siRNA cosupression of CXCR4 and CCR5 coreceptors by a specific lentiviral vector. AIDS Res. Ther. 2, 1-12.
4. BARRE-SINOUSSI, F., CHERMAN, J.-C., REY, R., NUGEYRE, M.T., CHAMARET, S., GRUEST, J., DAUGUET, C., AXLER-BLIN, C., VEZINET-BRUN, F., ROUZIOUX, C., ROZENBAUM, W., and MONTAGNIER, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871.
5. BERKHOUT, B. (2004). RNA interference as an antiviral approach: targeting HIV-1. Curr. Opin. Mol. Ther. 6, 141-145.
6. BHATTACHARYA, T., DANIELS, M., HECKERMAN, D., FOLEY, B., FRAHM, N., KADIE, C., CARLSON, J., YUSIM, K., MCMAHON, B., GASCHEN, B., MALLAL, S., MULLINS, J.I., NICKLE, D.C., HERBECK, J., ROUSSEAU, C., LEARN, G.H., MIURA, T., BRANDER, C., WALKER, B., and KORBER, B. (2007). Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315, 1583-1586.
7. BODEN, D., PUSCH, O., LEE, F., TUCKER, L., and RAMRATNAM, B. (2003). Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77, 11531-11535.
8. BODEN, D., PUSCH, O., LEE, F., TUCKER, L., and RAMRATNAM, B. (2004). Efficient gene transfer of HIV-1-specific short hairpin RNA into human lymphocytic cells using recombinant adeno-associated virus vectors. Mol. Ther. 9, 396-402.
9. CASTANOTTO, D., LI, H., and ROSSI, J.J. (2002). Functional siRNA expression from transfected PCR products. RNA 8, 1454-1460.
10. CHIU, Y.L., CAO, H., JACQUE, J.M., STEVENSON, M., and RANA, T.M. (2004). Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J. Virol. 78, 2517-2529.
11. COBURN, G.A., and CULLEN, B.R. (2002). Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76, 9225-9231.
12. CONNOR, R.I., CHEN, B., CHOE, S., and LANDAU, N.R. (1995). Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology 206, 935-944.
13. DAAR, E.S., and RICHMAN, D.D. (2005). Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res. Hum. Retroviruses 21, 343-357.
14. DAS, A.T., BRUMMELKAMP, T.R., WESTERHOUT, E.M., VINK, M., MADIREDJO, M., BERNARDS, R., and BERKHOUT, B. (2004). Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78, 2601-2605.
15. DIALLO, M., ARENZ, C., SCHMITZ, K., SANDHOFF, K., and SCHEPERS, U. (2003). Long endogenous dsRNAs can induce complete gene silencing in mammalian cells and primary cultures. Oligonucleotides 13, 381-392.
16. ELBASHIR, S.M., LENDECKEL, W., and TUSCHL, T. (2001). RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200.
17. GALLO, R.C., SALAHUDDIN, S.Z., POPOVIC, M., SHEARER, G.M., KAPLAN, M., HAYNES, B.F., PALKER, T.J., REDFIELD, R., OLESKE, J., SAFAI, B., et al. (1984). Frequent detection and isolation of cytopathic retrovirus (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224, 500-503.
18. GRIMM, D., and KAY, M.A. (2007). Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol. Ther. 15, 878-888.
19. GRIMM, D., STREETZ, K.L., JOPLING, C.L., STORM, T.A., PANDEY, K., DAVIS, C.R., MARION, P., SALAZAR, F., and KAY, M.A. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541.
20. HE, J., CHOE, S., WALKER, R., DI MARZIO, P., MORGAN, D.O., and LANDAU, N.R. (1995). Human immunodeficiency virus type 1 Viral Protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69, 6705-6711.
21. JACQUE, J., TRIQUES, K., and STEVENSON, M. (2002). Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438.
22. JEENINGA, R.E., HOOGENKAMP, M., ARMAND-UGON, M., DE BAAR, M., VERHOEF, K., and BERKHOUT, B. (2000). Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 74, 3740-3751.
23. KONSTANTINOVA, P., DE VRIES, W., HAASNOOT, J., TER BRAKE, O., DE HAAN, P., and BERKHOUT, B. (2006). Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther. 13, 1403-1413.
24. KONSTANTINOVA, P., TER BRAKE, O., HAASNOOT, J., DE HAAN, P., and BERKHOUT, B. (2007). Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome. Retrovirology 4, 15.
25. LASSEN, K., HAN, Y., ZHOU, Y., SILICIANO, J., and SILICIANO, R.F. (2004). The multifactorial nature of HIV-1 latency. Trends Mol. Med. 10, 525-531.
26. LEE, N.S., DOHJIMA, T., BAUER, G., LI, H. T., LI, M., EHSANI, A., SALVATERRA, P., and ROSSI, J.J. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 19, 500-505.
27. LI, M., and ROSSI, J.J. (2005). Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol. 309, 261-272.
28. MORRIS, K.V. (2006). Therapeutic potential of siRNA-mediated transcriptional gene silencing. Biotechniques Suppl., 7-13.
29. MORRIS, K.V., and ROSSI, J.J. (2004). Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. Curr. HIV Res. 2, 185-191.
30. MORRIS, K.V., and ROSSI, J.J. (2006). Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 13, 553-558.
31. NISHITSUJI, H., IKEDA, T., MIYOSHI, H., OHASHI, T., KANNAGI, M., and MASUDA, T. (2004). Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. Microbes Infect. 6, 76-85.
32. NISHITSUJI, H., KOHARA, M., KANNAGI, M., and MASUDA, T. (2006). Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J. Virol. 80, 7658-7666.
33. NOVINA, C.D., MURRAY, M.F., DYKXHOORN, D.M., BERESFORD, P.J., RIESS, J., LEE, S., COLLMAN, R.G., LIEBERMAN, J., SHANKAR, P., and SHARP, P.A. (2002). siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681-686.
34. PALELLA, F.J., JR., DELANEY, K.M., MOORMAN, A.C., LOVELESS, M.O., FUHRER, J., SATTEN, G.A., ASCHMAN, D.J., and HOLMBERG, S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860.
35. PARK, W.S., MIYANO-KUROSAKI, N., HAYAFUNE, M., NAKAJIMA, E., MATSUZAKI, T., SHIMADA, F., and TAKAKU, H. (2002). Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res. 30, 4830-4835.
36. PASSMAN, M., WEINBERG, M., KEW, M., and ARBUTHNOT, P. (2000). In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem. Biophys. Res. Commun. 268, 728-733.
37. PEDEN, K., EMERMAN, M., and MONTAGNIER, L. (1991). Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185, 661-672.
38. PING, Y.H., CHU, C., CAO, H., JACQUE, J.M., STEVENSON, M. and RANA, T.M., (2004). Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology 1, 46.
39. ROSSI, J.J. (2006). RNAi as a treatment for HIV-1 infection. Biotechniques Suppl, 25-29.
40. SLEDZ, C.A., HOLKO, M., DE VEER, M.J., SILVERMAN, R.H., and WILLIAMS, B.R. (2003). Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839.
41. STRAT, A., GAO, L., UTSUKI, T., CHENG, B., NUTHALAPATY, S., MATHIS, J.M., ODAKA, Y., and GIORDANO, T. (2006). Specific and nontoxic silencing in mammalian cells with expressed long dsRNAs. Nucleic Acids Res. 34, 3803-3810.
42. SURABHI, R.M., and GAYNOR, R.B. (2002). RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J. Virol. 76, 12963-12973.
43. TRAN, N., RAPONI, M., DAWES, I.W., and ARNDT, G.M. (2004). Control of specific gene expression in mammalian cells by co-expression of long complementary RNAs. FEBS Lett. 573, 127-134.
44. UNAIDS. (2005). AIDS Epidemic Update December 2005. pp. 1-98.
45. WATANABE, T., SUDOH, M., MIYAGISHI, M., AKASHI, H., ARAI, M., INOUE, K., TAIRA, K., YOSHIBA, M., and KOHARA, M. (2006). Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Ther. 13, 883-892.
46. WEINBERG, M.S., ELY, A., BARICHIEVY, S., MUFAMADI, S., CARMONA, S., and ARBUTHNOT, P. (2007). Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol. Ther. 15, 534-541.
47. WESTERHOUT, E.M., OOMS, M., VINK, M., DAS, A.T., and BERKHOUT, B. (2005). HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 33, 796-804.
48. WILLIAMSON, C., MORRIS, L., MAUGHAN, M.F., PING, L.H., DRYGA, S.A., THOMAS, R., REAP, E.A., CILLIERS, T., VAN HARMELEN, J., PASCUAL, A., RAMJEE, G., GRAY, G., JOHNSTON, R., KARIM, S.A., and SWANSTROM, R. (2003). Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res. Hum. Retroviruses 19, 133-144.
49. YAMAMOTO, T., OMOTO, S., MIZUGUCHI, M., MIZUKAMI, H., OKUYAMA, H., OKADA, N., SAKSENA, N.K., BRISIBE, E.A., OTAKE, K., and FUJI, Y.R. (2002). Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replication. Microbiol. Immunol. 46, 809-817.
50. YE, Y., DE LEON, J., YOKOYAMA, N., NAIDU, Y., and CAMERINI D. (2005); DBR1 siRNA inhibition of HIV-1 replication. Retrovirology 2, 63.
51. YOSHINARI, K., MIYAGISHI, M., and TAIRA, K. (2004). Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res. 32, 691-699.